Fulminant hepatitis is significantly increased in hepatitis B carriers after allogeneic bone marrow transplantation

Transplantation

Volumn 67, Issue 11, 1999, Pages 1425-1433

  Chen, Po Min ^a   Chiou, Tzeon Jye ^a   Fan, Frank S ^a   Liu, Jacqueline Ming ^b   Hsieh, Ruey Kuen ^a   Yen, Chueh Chuan ^a   Wang, Wei Shu ^a   Liu, Jin Hwang ^a  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; ALLOGRAFT; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CHEMOTHERAPY; CLINICAL ARTICLE; DISEASE CARRIER; ENDEMIC DISEASE; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HEPATITIS B; HUMAN; LIVER FUNCTION; MALE; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROPHYLAXIS; RISK ASSESSMENT; RISK FACTOR; SCHOOL CHILD; VIRUS CARRIER;

ADOLESCENT; ADULT; ALANINE TRANSAMINASE; ANALYSIS OF VARIANCE; ANTIBODIES, VIRAL; BONE MARROW TRANSPLANTATION; CARRIER STATE; CAUSE OF DEATH; CHILD; FEMALE; HEPACIVIRUS; HEPATITIS; HEPATITIS ANTIBODIES; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; LIVER FUNCTION TESTS; MALE; SURVIVAL ANALYSIS; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 0033564450     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199906150-00006     Document Type: Article

References (39)

1. Thomas ED. Marrow transplantation of malignant disease. J Clin Oncol 1983; 1: 517.
2. Tutschka PJ, Copelan EA, Kapoor N. Replacing total body irradiation with busulfan as conditioning of patients with leukemia for allogeneic marrow transplantation. Transplant Proc 1989; 21: 2952.
3. Thomas ED, Storb R, Fefer A, et al. Aplastic anemia treated by marrow transplantation. Lancet 1972; 1: 284.
4. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation 1974; 18: 295.
5. Thomas ED, Storb R, Clift RA, et al. Bone-marrow transplantation (II). N Engl J Med 1975; 292: 895.
6. Shulman HM, Sale GE, Lerner KG, et al. Chronic cutaneous graft-versus-host disease in man. Am J Pathol 1978; 91: 545.
7. Shulman HM, Sullivan KM, Weiden PL, et al. Chronic graft-versus-host disease syndrome in man: a long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69: 204.
8. Mc Donald GB, Hinds MS, Fisher LD, et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med 1993; 118: 255.
9. Vento S, Cainelli F, Mirandola F, et al. Fulminant hepatitis on withdrawal of chemotherapy in carriers of hepatitis C virus. Lancet 1996; 347: 92.
10. Chen PM, Fan FS, Hsieh RK, et al. Liver disease in patients with liver dysfunction prior to bone marrow transplantation. Bone Marrow Transplant 1992; 9: 415.
11. Chen PM, Fan S, Liu CJ, et al. Changing of hepatitis B virus markers in patients with bone marrow transplant. Transplant 1990; 49: 708.
12. Chen PM, Liu JH, Fan FS, et al. Liver disease after bone marrow transplantation: the Taiwan experience. Transplant 1995; 59: 1139.
13. Locasciulli A, Bacigalupo A, Vanlint MT, et al. Hepatitis C virus infection in patients undergoing marrow transplantation. Transplant 1991; 52: 315.
14. Fan FS, Tzeng CH, Hsiao KI, Hu ST, Lin WT, Chen PM. Withdrawal of immunosuppressive therapy in allogeneic bone marrow transplantation reactivates chronic viral hepatitis C. Bone Marrow Transplant 1991; 8: 417.
15. Bird GL, Smith H, Portmann B, Alexander GJ, Williams R. Acute liver decompensation on withdrawal of cytotoxic chemotherapy and immunosuppressive therapy in hepatitis B carriers. Q J Med 1989; 73: 895.
16. Papatheodoridis GV, Delladetsima JK, Kavallierou L, Kapranos N, Tassopoulos NC. Fulminant hepatitis due to Epstein-Barr virus infection. J Hematol 1995; 23: 348,
17. Chen DS, Kuo GL, Sung JL, et al. Hepatitis C virus infection in an area hyperendemic for hepatitis B and chronic liver disease: the Taiwan experience. J Infect Dis 1990; 162: 817.
18. Dienstag JL, Isselbacher KJ. Acute viral hepatitis: Harrison's principles of internal medicine. 1998; 295: 1677.
19. Rakela J, Redeker AG, Weliky B. Effect of short-term prednisolone therapy on aminotransferase levels and hepatitis B virus markers in chronic type B hepatitis. Gastroenterology 1983; 84: 956.
20. Cheng AL. Steroid free chemotherapy decrease the risk of hepatic flare up in hepatitis B virus carriers with non-Hodgkin's lymphoma. Blood 1996; 87: 1202.
21. Webster A, Brenner MK, Prentice HG, Griffiths PD. Fatal hepatitis B reactivation after autologous bone marrow transplantation. Bone Marrow Transplant 1989; 4: 207.
22. Martin BA, Rowe JM, Kouides PA, DiPersio JF. Hepatitis B reactivation following allogeneic bone marrow transplantation: case report and review of the literature. Bone Marrow Transplant 1995; 15: 145.
23. Gupta S, Govinderajan S, Fong T, Redeker AG. Spontaneous reactivation in chronic hepatitis B: patterns and natural history. J Clin Gastroenterol 1990; 12: 562.
24. Chu CM, Liaw YF. The incidence of fulminant hepatic failure in acute viral hepatitis in Taiwan: increased risk in patients with pre-existing HBsAg carrier state. Infection 1990; 18: 200.
25. Mertens T, Kock J, Hampl W, et al. Reactivated fulminant hepatitis B virus replication after bone marrow transplantation: clinical course and possible treatment with ganciclovir. J Hepatol 1996; 25: 968.
26. Tzeng CH, Hsieh RK, Fan S, et al. Bone marrow transplantation for severe aplastic anemia: a study of 21 Chinese patients in Taiwan. Transplant 1992; 53: 569.
27. Locasciulli A, Bacigalupo A, Alberti A, et al. Predictability before transplant of hepatic complications following allogeneic bone marrow transplantation. Transplantation 1989; 48: 68.
28. Koike K, Lino S, Kurai K, Mitamura K, Endo Y, Oka H. IgM anti-HBc in anti-HBe positive chronic type B hepatitis with acute exacerbations. Hepatology 1987; 7: 573.
29. Cox DR. Regression models and life tables. J R Stat Soc (B) 1972; 34: 187.
30. Jerrod H, ZAR. Biostatistical analysis. Englewood Cliffs, NJ: Prentice-Hall, 1984; 390.
31. Fless JL. Statistical methods for rates and proportions, 2nd Ed. New York: John Wiley & Sons, 1981; 143.
32. Yagisawa T, Toma H, Tanabe K et al. Long term outcome of renal transplantation in hepatitis B surface antigen-positive patients in cyclosporin era. Am J Nephrol 1997; 17: 440.
33. Mc Donald GB, Shulman HM, Wolford JL, Spencer GD. Liver disease after human marrow transplantation. Semin Liver Dis 1987; 7: 210.
34. Jackson LD, Song E. Cyclosporin in the treatment of corticosteroid resistant autoimmune chronic active hepatitis. Gut 1995; 36: 459.
35. Shevach EM. The effects of cyclosporin on the immune system. Annu Rev Immunol 1985; 3: 397.
36. Omata F, Ide H, Ito T, Shibayama Y, Takahashi H, Ueno F. Interferon therapy for fulminant hepatitis associated with precore region mutation in hepatitis B virus carrier. Am J Gastroenterol 1996; 91: 1673.
37. Yoshiba M, Sekiyama K, Inoue K, Fujita R. Interferon and cyclosporin A in the treatment of fulminant viral hepatitis. J Gastroenterol 1995; 30: 67.
38. Angus P, Richards M, Bowden S, et al. Combination antiviral therapy controls severe post-liver transplant recurrence of hepatitis B virus infection. J Gastroenterol Hepatol 1993; 8: 353.
39. Colacino JM, Staschke KA. The identification and development of antiviral agents for the treatment of chronic hepatitis B virus infection. Prog Drug Res 1998; 50: 259